This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.


Endocrine Hypertension

Edited by Edited by Karel Pacak (National Institute of Child Health and Human Development, NIH, Bethesda, MD), and Graeme Eisenhofer (National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD)
Endocrine Hypertension

Published: October 2002

Volume 970

Learn More

Hypertension is a major risk factor for stroke and cardiovascular disorders. An endocrinologic cause such as glucocorticoid or catecholamine excess or hyperaldosteronism is present in at least 5-10% of patients suffering from hypertension. Overproduction of these hormones is often caused by tumors of the adrenal and pituitary gland. The diagnosis of the respective underlying endocrine disorder has been facilitated by improved conventional imaging modalities and hormonal testing procedures and assays. Several recent genetic, biochemical, and radiologic discoveries and approaches have had an impact on the management of endocrine hypertension.